Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186
Policy Forum
Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan
Sho SaitoKayoko HayakawaAyako MikamiShinyu IzumiHideki FunazakiShinobu AshidaWataru SugiuraHaruhito SugiyamaNorihiro KokudoNorio Ohmagari
Author information

2021 Volume 3 Issue 2 Pages 62-66


Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan, China, has spread globally very rapidly. The number of COVID-19 patients increased in Japan from late March to early April 2020. Since COVID-19 treatment methods with antiviral drugs were not established in March 2020, clinical trials began at a rapid pace worldwide. We participated in a global investigator-initiated clinical trial of the antiviral drug remdesivir. It took approximately two months to prepare for and start patient enrollment, 26 days to enroll all patients in Japan, and 32 days from the end of enrollment to the release of the first report, a fairly quick response overall. In the course of this clinical trial, we found some of the critical issues related to conducting an infectious disease clinical trial in Japan need to be addressed and tackled to support a rapid response. These included such things as the necessity of a research network to promote clinical research, a framework for a rapid review system of clinical trial notification, and better cooperation with outsourced teams. Furthermore, for Japan to take the lead in global collaborative research and development in the field of infectious diseases, it is necessary to develop further human resources and organization on a national basis. It is indispensable for Japan to establish a clinical trial system at the national level to prepare for future emerging and re-emerging infectious diseases.

Content from these authors
© 2021 National Center for Global Health and Medicine
Previous article Next article